| Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ... New England journal of medicine 384 (5), 403-416, 2021 | 10948 | 2021 |
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial BF Haynes, PB Gilbert, MJ McElrath, S Zolla-Pazner, GD Tomaras, ... New England Journal of Medicine 366 (14), 1275-1286, 2012 | 2141 | 2012 |
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial SP Buchbinder, DV Mehrotra, A Duerr, DW Fitzgerald, R Mogg, D Li, ... The Lancet 372 (9653), 1881-1893, 2008 | 2029 | 2008 |
| Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing … M Li, F Gao, JR Mascola, L Stamatatos, VR Polonis, M Koutsoukos, ... Journal of virology 79 (16), 10108-10125, 2005 | 1281 | 2005 |
| Randomized, double‐blind, placebo‐controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV‐1 vaccine among injection drug users in Bangkok, Thailand P Pitisuttithum, P Gilbert, M Gurwith, W Heyward, M Martin, ... The Journal of infectious diseases 194 (12), 1661-1671, 2006 | 1048 | 2006 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 1047 | 2022 |
| Evidence for antibody as a protective correlate for COVID-19 vaccines KA Earle, DM Ambrosino, A Fiore-Gartland, D Goldblatt, PB Gilbert, ... Vaccine 39 (32), 4423-4428, 2021 | 902 | 2021 |
| Effect of dengue serostatus on dengue vaccine safety and efficacy S Sridhar, A Luedtke, E Langevin, M Zhu, M Bonaparte, T Machabert, ... New England Journal of Medicine 379 (4), 327-340, 2018 | 746 | 2018 |
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies MS Seaman, H Janes, N Hawkins, LE Grandpre, C Devoy, A Giri, ... Journal of virology 84 (3), 1439-1452, 2010 | 737 | 2010 |
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ... New England Journal of Medicine 369 (22), 2083-2092, 2013 | 720 | 2013 |
| Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana S Weiser, W Wolfe, D Bangsberg, I Thior, P Gilbert, J Makhema, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 34 (3), 281-288, 2003 | 644 | 2003 |
| Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase HM El Sahly, LR Baden, B Essink, S Doblecki-Lewis, JM Martin, ... New England Journal of Medicine 385 (19), 1774-1785, 2021 | 576 | 2021 |
| Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a … I Thior, S Lockman, LM Smeaton, RL Shapiro, C Wester, SJ Heymann, ... Jama 296 (7), 794-805, 2006 | 534 | 2006 |
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 M Rolland, PT Edlefsen, BB Larsen, S Tovanabutra, E Sanders-Buell, ... Nature 490 (7420), 417-420, 2012 | 491 | 2012 |
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination NL Yates, HX Liao, Y Fong, A DeCamp, NA Vandergrift, WT Williams, ... Science translational medicine 6 (228), 228ra39-228ra39, 2014 | 487 | 2014 |
| Prevalence and predictive value of intermittent viremia with combination HIV therapy DV Havlir, R Bassett, D Levitan, P Gilbert, P Tebas, AC Collier, MS Hirsch, ... Jama 286 (2), 171-179, 2001 | 481 | 2001 |
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial PB Gilbert, ML Peterson, D Follmann, MG Hudgens, DP Francis, ... The Journal of infectious diseases 191 (5), 666-677, 2005 | 473 | 2005 |
| Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG GD Tomaras, G Ferrari, X Shen, SM Alam, HX Liao, J Pollara, ... Proceedings of the National Academy of Sciences 110 (22), 9019-9024, 2013 | 458 | 2013 |
| Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine DE Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, ... New England Journal of Medicine 373 (21), 2025-2037, 2015 | 453 | 2015 |
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family M Bonsignori, J Pollara, MA Moody, MD Alpert, X Chen, KK Hwang, ... Journal of virology 86 (21), 11521-11532, 2012 | 448 | 2012 |
